Submit a manuscript Sign up for article alerts Contact us Support

RSS

Latest comments

Expected poor absorption of chewed raltegravir in HIV patients with severe intestinal impairment (Cristina Gervasoni, 22 April 2015)

Spinner and Coworkers have recently reported a case of an HIV-infected patient on raltegravir (RAL) maintenance therapy which required rifampicin for the treatment of disseminated Mycobacterium Avium infection [1]. By performing detailed RAL pharmacokinetic evaluations before and after adjusting RAL to the recommended dose of 800 mg BID the authors found comparable RAL AUC and Cmax values for 800 mg chewed vs. swallowed RAL, as well as for 400 mg chewed vs. swallowed RAL, thus providing conflicting results compared with our previous findings [2,3]. We believe, however, that these discrepancies are only apparent, being mainly biased by relevant confounding factors identified in this patient... read full comment

Comment on: Spinner et al. AIDS Research and Therapy, 12:1

Questions about anlaysis of data (Andrew Baughman, 18 October 2012)

I enjoyed reading this informative report, which will be useful to others researching HIV prevalence among street... read full comment

Comment on: Karmacharya et al. AIDS Research and Therapy, 9:25

ART (David Flora, 30 March 2012)

ART is indeed a revolution in the field of Aids Control and
Pcr Effeciency read full comment

Comment on: Steegen et al. AIDS Research and Therapy, 6:12